Thyroid malignancy rates according to the Bethesda reporting system in Israel - A multicenter study.
Adult
Aged
Biopsy, Fine-Needle
Clinical Laboratory Services
/ standards
Deglutition Disorders
/ etiology
Dyspnea
/ etiology
Female
Humans
Israel
Lymphadenopathy
/ etiology
Male
Middle Aged
Patient Selection
Predictive Value of Tests
Retrospective Studies
Risk Factors
Symptom Assessment
Thyroid Gland
/ pathology
Thyroid Neoplasms
/ classification
Thyroidectomy
Tumor Burden
Ultrasonography
Bethesda system
Malignancy rate
Nationwide
Risk of malignancy
Thyroid cancer
Journal
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
ISSN: 1532-2157
Titre abrégé: Eur J Surg Oncol
Pays: England
ID NLM: 8504356
Informations de publication
Date de publication:
06 2021
06 2021
Historique:
received:
01
02
2021
revised:
01
03
2021
accepted:
09
03
2021
pubmed:
23
3
2021
medline:
12
10
2021
entrez:
22
3
2021
Statut:
ppublish
Résumé
The Bethesda System for Reporting Thyroid Cytopathology was developed in 2007 to facilitate an accurate, reproducible communication of thyroid fine-needle aspiration (FNA) interpretations between clinicians and cytopathologists and to serve as a guide for treatment. Based on large patient series, the system details the risk of malignancy for each category as well as a suggested management for each FNA result. Though this system has been widely adopted, there are only few studies to determine whether results are applicable for Israel. A multicenter, retrospective analysis of medical charts of all patients who underwent thyroid surgery between January 1st, 2012 and December 31st, 2016 in four medical centers in Israel was performed. Data was analyzed for the overall risk of malignancy for the Bethesda system groups as well as comparison between the different laboratories performing the test. Records of 810 thyroidectomies in which preoperative cytological reports and final pathology were available and reviewed. The malignancy rates according to the Bethesda groups' I-VI for our cohort were: 27.8%, 17.6%, 41.4%, 41.4%, 86.9%, and 98.1% respectively. Similar results were seen when results were analyzed according to the different laboratories performing the tests. Post-surgical review of all Bethesda groups had higher malignancy rates than those reported in the original report. These results indicate a difference in the malignancy rates for the different Bethesda system groups in Israel compared to those reported. Physicians are encouraged to use data validated for their own country or patients' community in addition to published values.
Identifiants
pubmed: 33745793
pii: S0748-7983(21)00378-4
doi: 10.1016/j.ejso.2021.03.237
pii:
doi:
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
1370-1375Informations de copyright
Copyright © 2021 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest All authors have nothing to declare. There's no financial/personal interest or belief that could affect their objectivity.